Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN)

Historical Holders from Q4 2020 to Q3 2025

Symbol
VRDN on Nasdaq
Type / Class
Equity / Common Stock, $0.01 par value
Shares outstanding
82.1M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
93.2M
Holdings value
$2.01B
% of all portfolios
0.004%
Grand Portfolio weight change
0%
Number of holders
167
Number of buys
68
Number of sells
-83
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 15.14% $346M 16M Fairmount Funds Management LLC 23 Oct 2025
Venrock Healthcare Capital Partners III, L.P. 4.5% $48.4M 3.58M Venrock Healthcare Capital Partners III, L.P. 31 Dec 2024
Commodore Capital LP 3.9% -28% $69.1M -$23.7M 3.2M -25.6% Commodore Capital LP 30 Sep 2025

Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 93.2M $2.01B -$25M $21.58 167
2025 Q2 94.6M $1.32B +$45M $13.98 169
2025 Q1 91.4M $1.23B -$2.45M $13.48 174
2024 Q4 91M $1.75B +$57.7M $19.17 177
2024 Q3 86.9M $1.98B +$415M $22.75 163
2024 Q2 69.6M $906M -$23.3M $13.01 137
2024 Q1 71M $1.24B +$176M $17.51 134
2023 Q4 60.1M $1.31B +$204M $21.78 131
2023 Q3 50.2M $770M +$32.7M $15.34 122
2023 Q2 47.1M $1.12B +$92.3M $23.79 127
2023 Q1 43.1M $1.1B +$43.4M $25.44 134
2022 Q4 41.1M $1.2B +$91M $29.21 122
2022 Q3 38M $779M +$213M $20.51 104
2022 Q2 28.3M $328M +$27.2M $11.57 80
2022 Q1 24.9M $461M -$3.3M $18.49 71
2021 Q4 23.3M $460M +$113M $19.77 52
2021 Q3 13.6M $224M +$124M $16.45 38
2021 Q2 6M $110M +$18.4M $18.29 24
2021 Q1 5.06M $84.5M +$80.7M $16.71 28
2020 Q4 229K $3.77M +$3.77M $16.46 2